GlassScriptPhysician profile
John O Tyler
NPI 1275890329
$8,271.56
in general payments reported to CMS, 2019-2025
39 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,890 · 2020: $1,349 · 2021: $1,082 · 2022: $1,497 · 2023: $1,235 · 2024: $698 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,065.89 | 2019-2024 | Xarelto |
| Amgen INC. | $957.53 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $863.62 | 2019-2025 | |
| Pfizer INC. | $723.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $658.57 | 2021-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $494.66 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $430.44 | 2019-2023 | Lifevest |
| Amarin Pharma, INC. | $358.68 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $257.29 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $243.42 | 2020-2024 | Livalo |
| Novo Nordisk INC | $210.11 | 2022-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.39 | 2020-2024 | Jardiance |
| Esperion Therapeutics, INC. | $191.68 | 2020-2024 | Nexletol |
| Akcea Therapeutics, INC. | $162.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $136.16 | 2022-2025 | Verquvo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.